Overview

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

Status:
Completed

Trial end date:
2004-03-01

Target enrollment:

Participant gender:

Summary

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Sandoz

Treatments:

Etiracetam
Levetiracetam
Piracetam